Study ID | Drug | N | Age (Mean ± SD) | Sex (male) n (%) | Race (White) n | MMSE score (Mean ± SD) | AChEI or memantineuse, n (%) | APOE ε4 status carrier no. (%) | ADAS-cog score (Mean ± SD) | DAD score (Mean ± SD) |
---|---|---|---|---|---|---|---|---|---|---|
SSalloway et al., 2009 [13] | Placebo | 107 | 67.9 ± 8.8 | 43 (40.2) | 102 (95.3) | 20.7 ± 3.1 | 103 (96.3) | 74 (69.8) | ….. | …. |
Bapineuzumab | 122 | 70.1 ± 9.6 | 661 (50.0) | 118 (96.7) | 20.9 ± 3.2 | 116 (95.1) | 72 (60.5) | ….. | ….. | |
Black et al., 2010 [15] | Placebo | 8 | 69.8 ± 10.7 | 11 (12.5) | 5 (62.5) | 20.8 | ..... | ..... | ..... | ..... |
Bapineuzumab 0.5 mg/kg | 6 | 74.67 ± 5.65 | 33 (50) | 4 (66.67) | 21.8 | ..... | ..... | ..... | ..... | |
Rinne et al., 2010 [14] | Placebo | 7 | 70 ± 8·81 | 33 (43) | 7 (100) | 22·29 ± 2·69 | 7 (100) | 5 (71) | 19·19 ± 5·27 | 93·78 ± 8·24 |
Bapineuzumab | 19 | 67·26 ± 8·60 | 311 (57.9) | 19 (100) | 21·00 ± 2·33 | 19 (100) | 12 (63) | 22·26 ± 7·65 | 84·38 ± 11·95 | |
Salloway et al., 2014 (Carrier) [16] | Placebo | 432 | 72.3 ± 8.4 | 190 (44) | 420 (97.2) | 20.7 ± 3.2 | 400 (92.6) | 432 (100) | 23.9 ± 9.5 | 79.4 ± 18.9 |
Bapineuzumab 0.5 mg/kg | 658 | 72.0 ± 8.0 | 300 (45.6) | 624 (94.8) | 20.8 ± 3.1 | 606 (92.1) | 658 (100) | 23.5 ± 9.4 | 80.9 ± 17.3 | |
Salloway et al., 2014 (Non-Carrier) [16] | Placebo | 493 | 71.9 ± 10.1 | 245 (49.7) | 469 (95.1) | 21.2 ± 3.2 | 442 (89.7) | 493 (100) | 23.5 ± 9.4 | 80.5 ± 19.2 |
Bapineuzumab 0.5 mg/kg | 314 | 73.1 ± 9.3 | 149 (47.5) | 298 (94.9) | 21.2 ± 3.4 | 281 (89.5) | 314 (100) | 22.4 ± 9.7 | 80.0 ± 18.1 | |
Bapineuzumab 1 mg/kg | 307 | 73.5 ± 9.1 | 132 (42.9) | 292 (95.1) | 21.2 ± 3.3 | 278 (90.6) | 307 (100) | 22.2 ± 10 | 80.4 ± 18.8 | |
Arai et al., 2015 [17] | Placebo | 8 | 68.8 ± 8.9 | 4 (50) | ..... | 20.6 ± 3.0 | ..... | ..... | ..... | ..... |
Bapineuzumab 0.5 mg/kg | 6 | 72.2 ± 8.4 | 5 (83.3) | ..... | 21.0 ± 3.6 | ..... | ..... | ..... | ..... | |
Bapineuzumab 1 mg/kg | 6 | 72.2 ± 10.9 | 3 (50) | ..... | 21.0 ± 4.6 | ..... | ..... | ..... | ..... |